Decision Resources, Inc., announces the publication of Benign Prostatic Hyperplasia, a new study that evaluates trends that will drive market growth of therapies to treat this indication. We expect slow and steady growth in BPH prescription drug sales as a result of the following factors:
(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) * An increase in the prevalent population in most countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). * Improved public awareness of BPH and its treatment options. * Continued uptake of alpha blockers and 5-alpha-reductase inhibitors, the two leading classes for this indication. * The launch of several expensive novel agents.
We project the following developments in the major pharmaceutical segments for BPH:
Alpha blockers. Alpha blockers in general-and tamsulosin (Boehringer Ingelheim/Yamanouchi's Flomax) in particular-are regarded as the best available pharmacotherapy for BPH. We forecast that the continued uptake of this drug class will generate most of the future growth in the market for BPH therapies. The higher prices expected for promising novel agents, such as Sepracor's S-doxazosin will also drive sales growth for the class and for the market in general.
5-alpha-reductase inhibitors. The patent on finasteride (Merck & Co.'s Proscar) is scheduled to expire in the United States and several European countries toward the end of our 1999-2009 forecast period. In spite of generic competition, substantial opportunities exist for new 5-alpha-reductase inhibitors, provided that they fulfill their theoretical promise of a superior side-effect profile. However, it is unlikely that new 5-alpha-reductase inhibitors will challenge the dominance of the alpha blockers, given that they are useful only in a small subset of the patient population.
Phytopharmaceuticals. A wide variety of plant-based treatments for mild BPH are prescribed in Japan and Europe. In the United States, physicians estimate that at least 40% of BPH patients self-medicate with over-the-counter products. Although we expect plant-based therapies to remain popular with patients, we believe that prescriptions for this drug class will decline as more physicians begin to practice evidence-based medicine.
Benign Prostatic Hyperplasia offers invaluable market intelligence for pharmaceutical companies developing drugs to treat this indication. This study is a Mosaic product, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or email@example.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or firstname.lastname@example.org. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 201-369-3467
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553, or